CoChat

ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

Open access
Tarantino, P., Viale, G., Press, M.F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H.J., Carey, L.A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A.K., Lebeau, A., Loibl, S., Modi, S., Mosele, M.F., Provenzano, E., Pruneri, G., Reis-Filho, J.S., Rojo, F., Salgado, R., Schmid, P., Schnitt, S.J., Tolaney, S.M., Trapani, D., Vincent-Salomon, A., Wolff, A.C., Pentheroudakis, G., André, F., Curigliano, G. · 2023 · Annals of Oncology
Cited by 312

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

HER2-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer. The consensus included a multidisciplinary panel of 32 leading experts in the management of breast cancer from 9 different countries. The aim of the consensus was to develop statements on topics that are not covered in detail in the current ESMO Clinical Practice Guideline. The main topics identified for discussion were: (i) biology of HER2-low breast cancer; (ii) pathologic diagnosis of HER2-low breast cancer; (iii) clinical management of HER2-low metastatic breast cancer and (iv) clinical trial design for HER2-low breast cancer. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. A review of the relevant scientific literature was conducted in advance. Consensus statements were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the developed statements, including findings from the expert panel discussions, expert opinion and a summary of evidence supporting each statement.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2023.05.008

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 312

Metadata

Authors
Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A. K., Lebeau, A., Loibl, S., Modi, S., Mosele, M. F., Provenzano, E., Pruneri, G., Reis-Filho, J. S., Rojo, F., Salgado, R., Schmid, P., Schnitt, S. J., Tolaney, S. M., Trapani, D., Vincent-Salomon, A., Wolff, A. C., Pentheroudakis, G., André, F., & Curigliano, G.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2023-08
Volume
34
Issue
8
Pages
645-659
ISSN
0923-7534 (ISSN-L)
OpenAlex
W4378978327
Cited by
312
References
60
FWCI
32.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.